STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

Trial Profile

STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs RG 7716 (Primary) ; Ranibizumab
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms STAIRWAY
  • Sponsors Roche
  • Most Recent Events

    • 23 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 12 Feb 2018 According to a Roche media release, the company is committed to presenting data from all Phase II studies (BOULEVARD, AVENUE and STAIRWAY) at upcoming medical meetings and plans to discuss the phase III programme with health authorities following data assessment.
    • 31 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top